In conclusion, c‐FOS determines lenalidomide sensitivity and mediates drug resistance in MM cells as a co‐factor of IKZF1 and thus, could be a novel therapeutic target for further improvement of the prognosis of MM patients. The gene discussed is FOS; the disease is Miyoshi myopathy.